Literature DB >> 6160247

Bleomycin-induced scleroderma.

W R Finch, G P Rodnan, R B Buckingham, R K Prince, A Winkelstein.   

Abstract

Two men are reported who developed cutaneous fibrosis indistinguishable from that encountered in progressive systemic sclerosis (PSS, scleroderma) after treatment with the antitumor agent, bleomycin. In vitro study of the dermal fibroblasts of 1 patient showed that these cells synthesized increased quantities of collagen and therefore resembled cells derived from individuals with naturally occurring PSS. Bleomycin was shown to stimulate collagen production by cultured normal skin fibroblasts. Also, in 1 of the patients, bleomycin stimulated a lymphoproliferative response in vitro. These effects of bleomycin may be responsible for certain toxic reactions to this drug in the skin and lung.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160247

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts.

Authors:  Pei-Suen Tsou; Nadine N Talia; Adam J Pinney; Ann Kendzicky; Sonsoles Piera-Velazquez; Sergio A Jimenez; James R Seibold; Kristine Phillips; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2011-12-12

3.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

Review 4.  Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 5.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 6.  Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications.

Authors:  Ami A Shah; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

Review 7.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

8.  Recurrent metastatic breast cancer presenting with paraneoplastic scleroderma.

Authors:  Timothy David Reynolds; Sally Elizabeth Knights
Journal:  BMJ Case Rep       Date:  2014-03-11

9.  Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma.

Authors:  N Giordano; L Magaro; L Fattorini; P Marcucci; E Battisti; A Fioravanti; R Marcolongo
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

10.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.